Regulus Therapeutics Inc.
RGLS
Peringkat dalam Saham
#17287
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Harga Saham
$8.16
Terakhir disinkronkan: 2025-06-26
Kapitalisasi Pasar
$234.57M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-56.96%
Negara
US
Perdagangan Regulus Therapeutics Inc. (RGLS)
Kategori
Healthcare
Riwayat harga saham Regulus Therapeutics Inc. (RGLS)
Harga penutupan tertinggi: $18.90 pada 2024-08-01
Harga penutupan terendah: $25.97 pada 2018-04-01
Harga penutupan terendah: $25.97 pada 2018-04-01
Riwayat harga saham Regulus Therapeutics Inc. dari 2018 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2024 | 115.52% |
| 2023 | 128.77% |
| 2022 | -59.49% |
| 2021 | -66.20% |
| 2020 | -18.96% |
| 2019 | 28.12% |
| 2018 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.10 | -4.29% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
